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Figure 1
reduced the effects and the results were comparable to the con-
trol (Table 1). The addition of NOC18 signiﬁcantly enhanced the
effects of osteogenesis.
Conclusions: The results of the current study tested the hy-
pothesis that ESWT signiﬁcantly promotes osteogenesis of bone
marrow stromal cells. These innovative ﬁndings at least in part,
explain some of the mechanism of ESWT in hip necrosis.
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Purpose: Hand osteoarthritis (OA) is a common rheumatologic
disease, with an estimated prevalence of 38% for women and
24.5% for men, aged over 66 years. The objective of this study is to
compare the efﬁcacy and tolerability of a topical form of ketoprofen
(Ketum® 2.5% gel) versus oral diclofenac in the treatment of hand
OA.
Methods: This randomized, double-blind, double-dummy multicen-
tre clinical trial was conducted in France by 64 general physicians
between March 2007 and May 2008. Eligible patients included
men and women between 45 and 75 years old, with symptomatic
hand OA diagnosed according to the criteria of the American
College of Rheumatology and presenting with a base-line visual
analogue scale (VAS) score >40 mm and a Dreiser score ≥5.
Patients were randomly assigned to treatment with ketoprofen gel
plus placebo oral capsules, or placebo gel plus oral diclofenac
capsules (150 mg/d). Clinical assessments were performed 3 and
7 days after the initiation of the treatment. The primary endpoint
was deﬁned as the change of VAS scores ( VAS) between base-
line and last assessment. The analysis of the primary endpoint in
the per-protocol (PP) population was set as the primary analysis.
[-8mm to +8mm] was set as the equivalence interval (95% CI).
The full analysis set (FAS) and the PP populations were deﬁned
a priori in the statistical analysis plan. 61 patients were eliminated
patients), to compliance issues.
from the FAS population (n=395) due, for most of them (46
Abstract 332 – Table 1. Efﬁcacy results
Ketum® 2.5% gel (N=164) Diclofenac per os (N=170) Statistical analysis
Change of VAS score* at 7 days (mm) (primary endpoint) -33.2±21.0 -36.9±21.0 [ -1.1 ; 7.4 ]
conﬁdence interval of adjusted difference
Change of VAS score at 3 days (mm) -19.7±14.4 -21.3±15.5 0.427 (P value of ANCOVA)
Change of Dreiser score** at 7 days -6.0±4.4 -6.4±4.4 0.190 (P value of ANCOVA)
Change of Dreiser score at 3 days -3.6±3.1 -3.7±3.2 0.568 (P value of ANCOVA)
PGA on last assessment Very efﬁcient: 26.4% Very efﬁcient: 33.5% p=0.304 (bilateral Wilcoxon test)
Efﬁcient: 36.8% Efﬁcient: 31.8%
Moderalety efﬁcient: 27.0% Moderalety efﬁcient: 25.9%
Not efﬁcient: 9.8% Not efﬁcient: 8.8%
Pain auto-evaluation*** 31.2±8.7 29.5±8.9 p=0.078 (bilateral Wilcoxon test)
Therapeutic index**** (physician’s assessment) 2.86±1.00 3.09±0.97 p=0.033 (bilateral Wilcoxon test)
*Score from 0mm (no pain) to 100mm (maximal pain). **Score between 0 (no functional disability) and 30 (maximal functional disability). ***Area under the curve of
pain auto-evaluation from day 1 until day 7. ****Ratio of efﬁcacy/tolerability, comprised between 0,25 (worst ratio) and 4 (best ratio).
Results: 395 patients, predominantly females (74%), with a mean
age of 61 years were included. At base-line, mean VAS score and
Dreiser score were 70 mm and 12.5, respectively. Both treatment
arms were comparable for all the patients’ characteristics. In the
FAS population,  VAS scores at the end of the treatment [0,4mm
to 8,5mm] was slightly outside the equivalence interval. Whereas,
in the PP population (n= 334), the result of primary endpoint
was [-1,1mm to 7,4mm], demonstrating equivalence of efﬁcacy
between Ketum® 2.5% gel and diclofenac per os. Equivalence
was also shown for the following secondary efﬁcacy endpoints: 
VAS scores at 3 days,  Dreiser scores at 3 and 7 days, patient
efﬁcacy global assessment (PGA) and pain auto-evaluation (see
table 1). In terms of tolerability, there was no signiﬁcant difference
between both treatment groups (p=0.108).
Conclusions: This present study shows that, in the PP population,
Ketum® 2.5% gel and diclofenac per os are equivalent in terms of
efﬁcacy for the treatment of hand OA. These results support that
Ketum® could be an alternative therapy to oral NSAID treatments.
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Purpose: To identify and discuss ﬁve of the challenges experi-
enced during the designing, planning and execution of a RCT for
cartilage repair, using the pivotal study for BST-CarGel® (a new
medical device being investigated for the repair of focal articular
cartilage lesions) as an example. To summarize some aspects of
the trial and of the preclinical work that preceded its design.
Methods: Five major challenges in the process of planning and
conducting a pivotal trial for cartilage repair processes were iden-
tiﬁed and summarized. The preclinical work as the basis to design
the trial is summarized. The basics of the currently ongoing inter-
national pivotal trial are presented, as well as a brief description
of the clinical use of the device.
Results: Major challenges were: Lack of regulatory trial historical
comparators for cartilage repair: There were almost no bench-
marks when the trial was designed. An FDA guidance was issued
only in July 07. Identiﬁcation of appropriate primary, secondary
and tertiary endpoints becomes difﬁcult. Lack of agreement on the
appropriate tools to measure outcomes: Pain as primary outcome
vs structure of the new tissue. No test presently is the gold stan-
dard for cartilage repair; patient relevant tests, designed for OA or
ligament reconstruction, based on subjective input are still used.
S178 Poster Presentations
Biopsy analysis could be an ideal outcome but is sometimes ne-
glected by patients and review ethical boards; the use of advanced
MRI techniques as surrogate (T2 and dGEMRIC) is proposed. Dif-
ﬁculties to screen and determine eligibility of appropriate patients:
Preoperatory diagnosis of focal cartilage lesions is difﬁcult; until
an arthroscopy is performed there’s no certainty about the nature
of the lesion, as well as of concomitant pathologies. Potential
problems arising from concomitant surgeries (ACL reconstruc-
tions, multiple lesions) could become confounding factors. Patient
enrolment is a true challenge. Standardization of treatment: A high
degree of compliance with standardization of actions before, dur-
ing and after the surgical procedure is difﬁcult to obtain, especially
especially for an international trial. Physiotherapy is a critical point
and a consensus regarding this aspect of cartilage repair has not
been achieved. Need to design a trial which meets expectations of
third party payers: Due to needs in terms of regulatory and statisti-
cal compliance the indications have to be limited (size/depth of the
treated lesions, symptoms, patient age range), or the number of
patients needed to demonstrate if there are statistical differences
among groups will increase. Difﬁculty to show potential clinical
beneﬁt in the long term is another issue (12 months vs longer
and more costly trials). Third party payers are expecting evidence
that there’s a long lasting improvement. A 12 month interim anal-
ysis is being conducted on a subset of 41 patients after 1 year
postop. A similar analysis at 6 months suggested evidence of a
positive effect of BST-CarGel® on cartilage quantity/quality by MRI
compared to control group. No major safety issues occurred.
Conclusions: Trials for study of cartilage repair represent a true
challenge for basic researchers, clinicians, industry and for reg-
ulatory bodies. This study represents an important step toward
developing evidence-based treatment algorithms for cartilage re-
pair as well as for the identiﬁcation of the diverse hurdles that
those trials may represent. It also shows that the use of new
tissue structure as a primary endpoint, relying on advanced MRI
techniques is feasible.
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Purpose: To characterize the incidence and severity of gastroin-
testinal (GI) treatment-emergent adverse events (TEAEs) associ-
ated with analgesic treatment with tapentadol ER or oxycodone
CR in patients with moderate to severe chronic osteoarthritis knee
pain.
Abstract 334 – Table 1. Incidence and Severity of Selected Gastrointestinal TEAEs
TEAE, n (%) Placebo (n=337) Tapentadol ER (n=344) Oxycodone CR (n=342)
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe
All Gastrointestinal TEAEs 50 (56.8) 33 (37.5) 5 (5.7) 82 (55.4) 55 (37.2) 11 (7.4) 97 (42.2) 114 (49.6) 19 (8.3)
Nausea 14 (60.9) 7 (30.4) 2 (8.7) 48 (64.9) 21 (28.4) 5 (6.8) 59 (47.2) 54 (43.2) 12 (9.6)
Vomiting 4 (36.4) 4 (36.4) 3 (27.3) 11 (61.1) 6 (33.3) 1 (5.6) 28 (45.9) 30 (49.2) 3 (4.9)
Constipation 11 (50.0) 11 (50.0) 0 40 (61.6) 23 (35.4) 2 (3.1) 65 (51.6) 54 (42.9) 7 (5.6)
TEAE, treatment-emergent adverse event; ER, extended release; CR, controlled release.
Methods: In a randomized, double-blind, 15-week phase 3 trial,
patients with moderate to severe chronic osteoarthritis knee pain
received controlled, adjustable bid doses of tapentadol ER (100-
250 mg), oxycodone HCl CR (20-50 mg), or placebo over a 12-
week maintenance period, preceded by a 3-week titration period
to establish an optimal therapeutic dose. Efﬁcacy was assessed
using the change from baseline in average pain intensity over the
12-week maintenance period using the last observation carried
forward to impute missing values. The incidence and severity of
TEAEs were monitored over the 15-week treatment period.
Results: The intent-to-treat population included 1,023 patients.
Compared with placebo, tapentadol ER and oxycodone CR signif-
icantly reduced average pain intensity over the 12-week mainte-
nance period (least squares mean difference from placebo [stan-
dard error of the mean]: tapentadol ER, -0.7 [0.17], P<0.001;
oxycodone CR, -0.3 [0.17], P=0.049). The overall incidence of
TEAEs was 61.1%, 75.9%, and 87.4% in the placebo, tapentadol
ER, and oxycodone CR groups, respectively. The incidence of GI
TEAEs was 26.1% in the placebo group, 43.0% in the tapentadol
ER group, and 67.3% in the oxycodone CR group. Most TEAEs
were of mild to moderate intensity. Patients in the tapentadol ER
group reported lower incidences of GI TEAEs of moderate and se-
vere intensity than patients in the oxycodone CR group (Table). GI
TEAEs led to study discontinuation in 1.8% of the placebo group,
7.3% of the tapentadol ER group, and 26.9% of the oxycodone
CR group.
Conclusions: Tapentadol ER (100-250 mg bid) was associated
with numerically lower incidences of both moderate and severe GI
TEAEs and GI TEAEs leading to discontinuation compared with
oxycodone HCl CR (20-50 mg bid).
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Purpose: The purposes of the study were: (1) to examine the
relationship of regional adiposity with knee extensor strength,
pain, and physical function in older adults with knee osteoarthritis
(OA); (2) to investigate the association of knee extensor strength
with chair rise time, pain, and physical function; and (3) to explore
the relationship of leg extensor power with chair rise time and
4-meter walking speed.
Methods: 34 older adults with knee OA (65% female, mean age
= 71 yrs) were enrolled in the Strength Training in ARthritis Trial
(START) pilot study. Knee extensor strength was measured for the
most affected limb using a Kin-Com 125E Isokinetic Dynamometer
set at a speed of 30 deg/s. Leg extensor power (work done per
unit time) was assessed using a Nottingham Power Rig. Measures
of regional adiposity, percent lower extremity and trunk fat, were
obtained via a DXA scan. Chair rise time and 4-meter walking
